DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

NCT06077500 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Carcinoma (SCLC)

Interventions

DRUG: BI 764532
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Atezolizumab

Sponsor

Boehringer Ingelheim